31430-18-9
Nocodazole
CAS: 31430-18-9
Molecular Formula: C14H11N3O3S
31430-18-9 - Names and Identifiers
31430-18-9 - Physico-chemical Properties
| Molecular Formula | C14H11N3O3S |
| Molar Mass | 301.32 |
| Density | 1.490 |
| Melting Point | 300 °C (dec.) |
| Solubility | Soluble in DMSO (10 mg/ml);Soluble in Ethanol (1 mg/ml) |
| Appearance | Amber powder |
| Color | white |
| BRN | 1085978 |
| pKa | 10.67±0.10(Predicted) |
| Storage Condition | -20°C |
| Stability | Stable for 2 years as supplied. Solutions in DMSO may be stored at -20° for up to 2 months. |
| Refractive Index | 1.6740 (estimate) |
| MDL | MFCD00005588 |
| Use | A potent Tubulin production inhibitor and anti-neoplastic agent |
| In vitro study | Nocodazole is a high affinity ligand for cancer-related kinases, such as phosphorylated ABL, c-KIT, BRAF, and MEK, with K D values of 0.091 μm and 1.6 μm respectively, 1.8 M and 1.6 M,. In addition, the phosphorylation of ABL(E255K) and ABL(T315I) by Nocodazole, the K D values of BRAF(V600E) and PI3Kγ are 0.12 μm and 0.17 μm respectively, 1.1 μm and 1.5 μm. Nocodazole induces apoptosis in chronic lymphocytic leukemia cells; Inhibits insulin-stimulated glucose transport; Reduces apoptosis in human colon cancer cells; Impairs morphology and directional migration of medial ganglion crest cells. At high concentrations, Nocodazole rapidly depolymerizes microtubules in the cell, while at low concentrations it inhibits the dynamic instability of microtubules. Treating with Nocodazole after 6 hours of synchronized division phase cells, after adding different concentrations of paclitaxel, can cause G 1 phase arrest, the half inhibitory concentration is 4nm. Paclitaxel treated Nocodazole pretreated cells, in the absence of Nocodazole, cells can only form free microtubules, while in the presence of Nocodazole, it can form aggregated centrosome microtubules. By disrupting microtubules by binding to β-tubulin, Nocodazole can block disulfide bond formation and vesicle trafficking, inhibiting METH-induced apoptosis and lysosomal dysfunction. Pretreatment with Nocodazole significantly reduced METH-induced apoptosis. In iPSC, Nocodazole can double the HDR efficiency up to 30%. |
| In vivo study | The combined use of Ketoconazole and Nocodazole more strongly inhibited tumor volume and tumor weight in mice than alone. The apoptosis-inducing effect of the combination was also more pronounced than that of the combination alone in the COLO205 tumor transplantation model. |
31430-18-9 - Risk and Safety
| Risk Codes | R61 - May cause harm to the unborn child R40 - Limited evidence of a carcinogenic effect R36/37/38 - Irritating to eyes, respiratory system and skin. R34 - Causes burns R11 - Highly Flammable R68 - Possible risk of irreversible effects R63 - Possible risk of harm to the unborn child |
| Safety Description | S53 - Avoid exposure - obtain special instructions before use. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S16 - Keep away from sources of ignition. S36/37 - Wear suitable protective clothing and gloves. |
| UN IDs | 2811 |
| WGK Germany | 3 |
| RTECS | DD6521000 |
| HS Code | 29349990 |
| Hazard Class | 6.1(b) |
| Packing Group | III |
| Toxicity | sln-smc 1 ppm/16H MUREAV 141,15,84 |
Supplier List
Spot supply
Product Name: Nocodazole Visit Supplier Webpage Request for quotationCAS: 31430-18-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Nocodazole Visit Supplier Webpage Request for quotationCAS: 31430-18-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History